ReviewAdvances in experimental medicine and biology2025
ESC Seed Cell Resource Bank.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human embryonic stem cells (hESCs) play a critical role in advancing regenerative medicine, with significant potential in tissue engineering, disease modeling, and cell-based therapies. Following the derivation of the first hESC line and subsequent breakthroughs in induced pluripotent stem cell (iPSC) technology, global efforts have accelerated the progress of stem cell research and clinical applications. The development of high-standard stem cell banks worldwide has ensured the traceability, quality, and accessibility of these critical resources, enabling their safe translation to clinical use. The National Stem Cell Resource Center (NSCRC) advances the efforts in arranging and optimizing stem cell resources to support research and clinical needs. Through rigorous quality control system construction and encouraging innovation, the NSCRC has been accredited by ISO 20387 and ISO 17025. Now, the NSCRC has developed a broad spectrum of high-quality stem cell lines, securing independent intellectual property rights. These resources have facilitated clinical research, supported major scientific initiatives, and provided good practice experience for the international standardization of stem cells. Moreover, the focus on integrating organoid resources and establishing intelligent biobanks highlights the frontier correlation of stem cell research, promoting innovation, collaboration, and clinical translation to meet unmet medical needs.
Indexed as
Identifiers
41136836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.